Clinical trial
Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia…
NCT00323856 · Grifols Biologicals, LLC, Industry · Completed
Key facts
| NCT number | NCT00323856 |
|---|---|
| Title | Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A |
| Official title | Phase IV A Study of Immunologic Safety for Alphanate in Previously Treated Patients Diagnosed With Severe Hemophilia A |
| Lead sponsor | Grifols Biologicals, LLC, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Severe Hemophilia A |
| Intervention type | Drug |
| Interventions | Alphanate SD/HT |
| Enrollment | 51 |
| Start date | Apr 8, 2003 |
| Primary completion | Dec 11, 2018 |
| Completion | Dec 14, 2018 |
| First posted | May 10, 2006 |
| Last update posted | Jan 16, 2025 |
| Countries | Poland |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: